Improving patient access to life-enhancing medications

Mayne Pharma Group Limited has signed an exclusive license agreement with TherapeuticsMD, Inc. a NASDAQ listed company for three branded women’s health products and a portfolio of prenatal vitamins in the US (License Agreement)

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that following completion of the sale of Metrics Contract Services (Metrics) it intends to return up to $113 million to shareholders, through a combination of cash distributions.

Mayne Pharma Group Limited is pleased to announce the completion of the sale of Metrics Contract Services (Metrics) to Catalent Pharma Solutions, Inc. for US$475 million (approximately A$722 million at current exchange rates).

Mayne Pharma Group Limited is pleased to announce it has appointed Mr Shawn Patrick O’Brien as Chief Executive Officer and Managing Director effective 1 October 2022. This follows from the previously announced retirement of Mr Scott Richards and a comprehensive search for a successor.

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Mr David Petrie, has accepted an invitation to join the Board of Mayne Pharma, effective 1 September 2022.

Mayne Pharma’s CEO, Mr Scott Richards said, “At a group level, we reported annual revenue growth for the first time in five years. Excluding retail generics, the remaining businesses which represent more than 80% of reported gross profit grew 27% on the prior corresponding period (pcp).